Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer

Table 1 Correlation of cytoplasmic indoleamine-2,3-dioxygenase 1 expression with colorectal cancer clinicopathologic parameters

Characteristic	Total	Low IDO1	High IDO1	P-value
Sex				0.074
Male	52	22 (42.3)	30 (57.7)
Female	43	27 (62.8)	16 (37.2)
Age in yr				0.65
≥ 60	30	17 (56.7)	13 (43.3)
< 60	65	32 (49.2)	33 (50.8)
Cancers				0.93
Colon	46	24 (52.2)	22 (47.8)
Rectum	49	25 (51.0)	24 (49.0)
BMI				0.16
≥ 25	20	7 (35.0)	13 (65.0)
< 25	75	42 (56.0)	33 (44.0)
Tumor differentiation				0.47
Moderate and poor	78	42 (54.5)	35 (45.5)
Well	17	7 (41.2)	10 (58.8)
Colon cancer stage				0.52
3	20	12 (60.0)	8 (40.0)
2	26	12 (46.2)	14 (53.8)
T stage				0.69
4	29	14 (48.3)	15 (51.7)
2/3	17	10 (58.8)	7 (41.2)
N stage				0.96
1/2	20	11 (55.0)	9 (45.0)
0	26	13 (50.0)	13 (50.0)
Rectum cancer stage				0.67
3	24	11(45.8)	13 (54.2)
2	25	14 (46.0)	11 (44.0)
T stage				0.68
4	22	12 (55.6)	10 (45.4)
2/3	27	12 (44.4)	15 (55.6)
N stage				0.88
1/2	24	12 (50.0)	12 (50.0)
0	25	13 (52.0)	12 (48.0)
CEA in ng/mL				0.45
> 5	42	24 (57.1)	18 (42.9)
≤ 5	53	25 (47.2)	28 (42.8)
CA19-9 in U/mL				0.22
> 37	17	6 (35.3)	11 (64.7)
≤ 37	78	43 (55.1)	35 (44.9)
CD3 TILs				0.27
High	36	22 (61.1)	14 (38.9)
Low	59	28 (47.5)	31 (42.5)
CD8 TILs				0.96
High	22	12 (54.5)	10 (45.5)
Low	73	38 (52.5)	35 (47.5)
COX2				0.92
High	48	26 (54.2)	22 (45.8)
Low	47	24 (51.1)	23 (48.9)
Treatment group				0.58
Celecoxib	44	25 (56.8)	19 (43.2)
Non-celecoxib	51	25 (49.0)	26 (51.0)

Data are presented as n or n (%). BMI: Body mass index; CA: Cancer antigen; CEA: Carcinoembryonic antigen; COX2: Cyclooxygenase 2; CRC: Colorectal cancer; IDO1: Indoleamine-2,3-dioxygenase 1; TILs: Tumor-infiltrating lymphocytes.